BON Unveils Kombucha-Inspired Product, Inks $12 Million Strategic Sales Agreement with Qingshengyuan
Rhea-AI Summary
BON (Nasdaq: BON) announced on December 10, 2025 the launch of a kombucha-inspired beverage formulated to concentrate tea pigments and a non-exclusive strategic sales agreement with Shaanxi Qingshengyuan.
The 24-month agreement has a $12 million total contract value and appoints Qingshengyuan to sell and distribute BON's high-tea-pigment products across Greater China. The beverage uses a SCOBY fermentation process intended to increase tea pigment levels versus similar products. The release cites a projected $1 billion market opportunity for tea-pigment applications and positions the collaboration as a route to broaden commercialization and market awareness.
Positive
- $12 million 24-month strategic sales agreement
- Distribution across Greater China via Qingshengyuan
- Launch of kombucha-inspired product with enhanced tea pigments
- Company cites $1 billion market opportunity for tea-pigment applications
Negative
- Agreement is explicitly non-exclusive
- Contract term limited to 24 months, capping near-term visibility
News Market Reaction – BON
On the day this news was published, BON gained 8.16%, reflecting a notable positive market reaction. Argus tracked a peak move of +2.0% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $14M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: CNEY down 3.02%, while BSLK up 9.32% and others modestly positive. BON’s -4.89% move appears more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 25 | Sales cooperation deal | Positive | +0.6% | US$26M non-exclusive 36‑month tea pigment product agreement for Greater China. |
| Sep 09 | Product cooperation deal | Positive | +24.7% | US$18M agreement for second‑generation Apple Series health products distribution. |
| Sep 02 | AI research update | Positive | +5.0% | AI‑identified tea polyphenols with promising weight management potential in early tests. |
| Aug 05 | Nasdaq compliance | Positive | -2.3% | Confirmation of regained compliance with Nasdaq minimum bid price requirements. |
| Jul 30 | AI R&D launch | Positive | -3.6% | Launch of AI‑powered drug discovery initiative using TCM compound library. |
Positive commercial and R&D news often saw favorable or modestly positive reactions, while compliance/governance updates have previously coincided with negative price moves.
Over the last six months, BON reported several growth-focused developments. On Jul 30, it launched an AI-powered drug R&D business. On Aug 5, it regained Nasdaq bid-price compliance but entered a one-year monitoring period. Subsequent news highlighted an AI-driven weight management discovery and two sizable Greater China distribution agreements worth $18 million and $26 million. Today’s $12 million kombucha-inspired tea-pigment agreement continues this pattern of commercial partnerships aimed at expanding functional health product distribution.
Regulatory & Risk Context
The company has an amended Form F-3 shelf filed on 2025-11-07 to register up to $500,000,000 in various securities, enabling potential future capital raises subject to public float limits under General Instruction I.B.5.
Market Pulse Summary
The stock moved +8.2% in the session following this news. A strong positive reaction aligns with BON’s pattern of favorable responses to sizable distribution agreements, such as prior $18 million and $26 million deals. The new $12 million Qingshengyuan agreement continues this commercial expansion theme. Investors would need to weigh this against BON trading well below its 200-day MA and the existence of a $500,000,000 shelf, which together could influence how durable any sharp upside move might be.
Key Terms
symbiotic culture of bacteria and yeast medical
scoby medical
tea pigments technical
antioxidant activity medical
AI-generated analysis. Not financial advice.
As a global innovator in tea-pigment ingredients, BON has observed growing consumer demand for tea-based products that are "more efficient, more pure, and more scientific." In response, the Company has developed a kombucha-inspired beverage produced from premium tea, sugar, and a Symbiotic Culture of Bacteria and Yeast ("SCOBY"). The product undergoes a controlled natural fermentation process that maintains the tea's fresh aroma, sweet aftertaste, and lightly effervescent texture, while enhancing the extraction and concentration of tea pigments. As a result, the beverage contains higher levels of tea pigments compared to similar products.
Kombucha has become one of the fastest-growing functional beverage categories in recent years, driven by consumer interest in natural ingredients and perceived health benefits, particularly among younger consumers. BON's product is designed to align with these market trends and seeks to support category development through its ingredient-focused technology.
Tea pigments are natural, water-soluble pigment complexes formed during the fermentation and oxidation of tea leaves and are considered key functional compounds in tea. Scientific literature indicates that tea pigments contribute to the color and clarity of tea infusions and have been the subject of research regarding potential biological properties, including antioxidant activity and other areas of scientific interest.
As consumer preferences increasingly shift toward natural ingredients and as the functional food and beverage market expands, tea pigments are gaining broader commercial application as an alternative to synthetic additives. They are used in tea beverages, health-oriented consumer products, and other ingredient formulations within the food and beverage industry.
Driven by these trends, the market for tea-pigment-based ingredients has continued to grow. Industry sources project that the overall market opportunity for tea-pigment applications could reach approximately
Yongwei Hu, CEO and Chairman of BON, stated: "This strategic cooperation with Qingshengyuan represents an important step in expanding BON's presence in the functional product industry and supports the development and commercialization of our tea-pigment product portfolio. We expect that combining the resources and capabilities of both parties will help increase market awareness of our ingredient technologies and broaden the reach of our products among targeted consumer groups. Through this collaboration, we aim to advance product innovation, support broader adoption of health-focused concepts in the market, and further strengthen BON's positioning in both domestic and international markets. We believe this will support the Company's future revenue and earnings and further enhance long-term shareholder value."
About Bon Natural Life Limited ("BON")
BON is a
For more information, please contact:
Cindy Liu | IR
Email: bonnatural@appchem.cn
Safe Harbor Statement
This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes,""expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
View original content:https://www.prnewswire.com/news-releases/bon-unveils-kombucha-inspired-product-inks-12-million-strategic-sales-agreement-with-qingshengyuan-302636301.html
SOURCE Bon Natural Life Limited
FAQ
What did BON (BON) announce on December 10, 2025 regarding a new product?
How large is the BON and Qingshengyuan sales agreement announced December 10, 2025?
What geographic scope does the BON–Qingshengyuan agreement cover for BON (BON)?
Is the BON sales agreement with Qingshengyuan exclusive or non-exclusive?
How does BON describe the commercial opportunity for tea pigments in its December 10, 2025 announcement?
What is the expected commercial role of BON's kombucha-inspired beverage?
